Inve India ▾

Biocon share price & results

Biocon Limited· Healthcare

Results to
Jun 2026
Latest analysed call
Q1 FY27
Ownership as of
Sept 2026

Global biopharma group making biosimilars, insulins, generics and CRDMO services via Syngene.

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue4,336 ₹ crore+10.0% YoYQuarterly, as filedQuarter to Jun 2026Revenue from operations as filed.
Operating margin20.0 %+1.0 pts YoYOperating profit / revenueQuarter to Jun 2026For the quarter; a change is in percentage points.
Net profit137 ₹ crore+53.9% YoYQuarterly, as filedQuarter to Jun 2026Profit after tax as filed.
Return on equity2.61 %−3.3 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin0.48 %−10.8 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)9.84 %+7.5 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Revenue change against the same period one year earlier.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Jun 2026

Guidance

What management said, and what became of it

12 of 14 judged targets kept · 8 open · verdicts reflect calls analysed to Q1 FY27.

Biocon Limited management guidance track record on Inve: 22 targets tracked across analysed earnings calls (12 achieved, 2 missed, 8 open).

TargetOriginal wordingSaidLatest callVerdict
Biosimilars EBITDA MarginSustainable guidance of 22% to 23%
Call transcript, Q3 FY25 · 7 Feb 2025		Q3 FY25Q1 FY27:25% margin reported, in line with 'mid-20s' guidance.
Call transcript, Q1 FY27 · 6 Aug 2026		Achieved
Syngene (CRDMO) Revenue GrowthMaintaining annual guidance for FY26
Call transcript, Q2 FY26 · 12 Nov 2025		Q2 FY26Q1 FY27:Promise related to FY26 guidance remains missed. New guidance for FY27 is for single-digit revenue degrowth.
Call transcript, Q1 FY27 · 6 Aug 2026		Missed
Generics EBITDA MarginGet closer to 13%, 14% in 1 or 2 years
Call transcript, Q3 FY25 · 7 Feb 2025		Q3 FY25Q1 FY27:Margin reported at 7%, a sequential decline from 8% in Q4 FY26. Remains far from the 13-14% target.
Call transcript, Q1 FY27 · 6 Aug 2026		At Risk

Source: Inve Guidance Tracker for Biocon Limited · to Q1 FY27

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

2 of Biocon Limited's 22 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 19 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹332.45 +1.11% · +₹3.65

Last close 27 Oct 2026 · NSE · INR · Source: Inve

Performance −7.5% 1Y

₹350₹400₹450Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26Q2 FY26 — 12 Nov 2025Q3 FY26 — 13 Feb 2026Q4 FY26 — 8 May 2026Q1 FY27 — 6 Aug 2026

1Y: ₹359.5 on 24 Oct 2025 → ₹332.45. High ₹440.7 (16 Jul 2026), low ₹323.5 (23 Oct 2026).

Previous close
₹328.8
Market cap
₹54.5k Cr
52-week range
₹323.5 – ₹440.7
One year
−7.77%
Price to earnings (TTM to Jun 2026)
74.94×
Return on equity (TTM to Jun 2026)
2.61%

Overview

Symbol
NSE:BIOCON
Exchange
NSE
Currency
INR

What Biocon Limited does

Based on the company's own presentations, annual report and earnings calls.

Biocon Limited is a Bengaluru-headquartered biopharmaceutical group that develops, manufactures and markets biosimilar monoclonal antibodies, insulins and GLP-1 peptides, generic APIs and formulations, and offers contract research, development and manufacturing (CRDMO) services through its 52.4%-held subsidiary Syngene International. It earns through direct commercialisation of branded biosimilars and generics in regulated and emerging markets, and through fee-for-service CRDMO contracts for global pharma, biotech and agrochemical clients. The group also holds a minority stake in NASDAQ-listed Bicara Therapeutics for novel biologics discovery. Its integrated model spans in-house R&D, API and drug-product manufacturing, and country-specific commercial go-to-market structures.

Segments

  • Biosimilars
  • Generics
  • CRDMO Services
  • Novel Biologics
Countries with commercial reach
120+
Patients benefited through Generics & Biosimilars (FY25)
21.2+ million
Manufacturing locations
11
cGMP regulatory approvals
215+ from 25+ regulators
Biosimilar and GLP-1 portfolio
30+ biosimilars and 3 GLP-1 peptides
R&D footprint
500+ scientists across 3 R&D sites
Founded 1978Headquarters Bengaluru, IndiaEmployees 16,561 (31 March 2025) Company website

How the price took the results

close before → close after

Q1 FY27
+2.7%
6 Aug
Q4 FY26
−0.5%
8 May
Q3 FY26
+0.8%
13 Feb
Q2 FY26
+5.4%
12 Nov

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Your own record

Start an Inve Case for Biocon Limited

Free account: one company. Everything above stays public.

Write why you follow Biocon Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Learn to analyse Biocon Limited

Guides on how to read this kind of business and the numbers that matter.